Biosynth, a supplier of critical raw materials to the life science industry, has acquired VIO Chemicals, a Zurich-based company with leading chemical R&D expertise and a global network of large-scale manufacturing partners. The acquisition will expand Biosynth’s ability to secure its customers’ supply chains by bringing greater flexibility in scales for complex chemical manufacturing, with expertise across carbohydrates, nucleosides, intermediates, and specialty excipients, among others.
“Biosynth’s passion for chemistry has always been something that we have shared,” commented VIO Chemicals CEO and Founder, Dimitris Kalias. “We are both driven by both science and our customers’ needs, and I am excited for VIO to be part of the research, development, and manufacturing services that support our shared customers across a wide range of scales.”
VIO Chemicals is specialized in the custom design and production of specialty chemicals, intermediates and Active Pharmaceutical Ingredients (APIs). The story of VIO Chemicals began as a start-up company in Zurich, Switzerland in 2001. It has since grown to a global provider with a portfolio of 2,500 products delivered to the world's leading companies all over the Americas, over 20 European countries and Asia. The company has a production unit in China, an R6D office in Greece and sales offices around the globe.
CEO and President of Biosynth, Urs Spitz, was pleased to welcome Biosynth’s long-standing collaborator. “VIO Chemicals has a long standing relationship with Biosynth and is an excellent addition to our flagship Complex Chemicals division. We know that our customers want to stay working with us as their needs develop, so being able to offer flexibility and scope for greater scales of production, into the many metric tons, is an important part of that.”
(Press release / SK)
Picture: VIO Chemicals